Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 5/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.37 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17622509 | 0.88 | GAA (0.42) | GAAAKR1B1CA2CXCL8CAMK2A | |
| SCHEMBL5357198 | 0.83 | AKR1B1 (0.40) | GAAAKR1B1CA2CXCL8CAMK2A | |
| SCHEMBL4837065 | 0.83 | AKR1B1 (0.45) | AKR1B1CA2CXCL8CAMK2ACYP2C9 | |
| SCHEMBL4549702 | 0.79 | GAA (0.53) | GAACXCL8CHRM1 | |
| SCHEMBL7714917 | 0.79 | GAA (0.54) | GAACYP2C9 | |
| SCHEMBL19181631 | 0.78 | SIGMAR1 (0.43) | GAACYP2C9SLC9A1 | |
| SCHEMBL14793743 | 0.78 | CA2 (0.53) | GAAAKR1B1CA2CXCL8CAMK2A | |
| SCHEMBL7164323 | 0.76 | ABCB11 (0.40) | AKR1B1CA2CXCL8CAMK2ACYP2C9 | |
| SCHEMBL72627 | 0.75 | SMN1; SMN2 (0.41) | GAACYP2C9 | |
| SCHEMBL11164004 | 0.75 | CA2 (0.50) | GAAAKR1B1CA2CXCL8CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-7345179-B2 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-7345179-B2 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-7345179-B2 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | DAICHI PAHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | DAICHI PAHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | DAICHI PAHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1698611-A1 | PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1698621-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1623975-A1 | PROCESS FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | ALDH18A1, PLAAT4, ACSL4 | GAA 588/4885AKR1B1 1345/4885CA2 4104/4885 |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | ALDH18A1, PLAAT4, ACSL4 | GAA 588/4885AKR1B1 1345/4885CA2 4104/4885 |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | ACSL4, ALDH18A1, LTA | GAA 746/4885AKR1B1 317/4885CA2 2085/4885 |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | UGT1A4, VPS4B, CYP3A4 | GAA 102/4885AKR1B1 784/4885CA2 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.